HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and lowers the price target from $12 to $11.
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and lowers the price target from $12 to $11.